Literature DB >> 12386808

Cdk9, a member of the cdc2-like family of kinases, binds to gp130, the receptor of the IL-6 family of cytokines.

Giulia De Falco1, Luca Maria Neri, Maria De Falco, Cristiana Bellan, Zailin Yu, Antonio De Luca, Lorenzo Leoncini, Antonio Giordano.   

Abstract

Cdk9 is a member of the Cdc2-like family of kinases. It binds to members of the family of cyclin T (T1, T2a and T2b) and to cyclin K. The Cdk9/cyclin T complex appears to be involved in regulating several physiological processes. In fact Cdk9 is the kinase of the P-TEFb complex, involved in basal transcription. Cdk9 has also been described as the kinase of the TAK complex, homologous to P-TEFb and involved in HIV replication. Here we show that Cdk9 interacts with gp130, the receptor of the Interleukin-6 (IL-6) family of cytokines, which includes Leukemia Inhibitory Factor (LIF), Oncostatin M (OSM), Ciliary Neurotrophic Factor (CNTF), Interleukin-11 (IL-11) and Cardiotrophin (CT-1). IL-6 is a key regulator of hematopoiesis, immunological responses and inflammation. In addition, IL-6 plays a major role in the endocrine and nervous systems. Signal transduction by gp130 is mediated by physical interaction of the cytoplasmic region of gp130 with cellular kinases and results in the transcriptional activation of cellular and viral genes. We found that Cdk9 interacts in vitro with the cytoplasmic region of gp130 and we succeded in reproducing this interaction in vivo. Cdk9 expression was found both in the nucleus and in the cytoplasm. The binding occurring between Cdk9 and gp130 increased upon IL-6 stimulation. We also observed that Cdk9 synergized with IL-6 in inducing the activation of an IL-6-responsive reporter plasmid. In summary, these results point to a previously undisclosed role for Cdk9 in signal transduction.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12386808     DOI: 10.1038/sj.onc.1205967

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  10 in total

1.  Activation of P-TEFb at sites of dual HIV/TB infection, and inhibition of MTB-induced HIV transcriptional activation by the inhibitor of CDK9, Indirubin-3'-monoxime.

Authors:  Zahra Toossi; Mianda Wu; Christina S Hirsch; Harriet Mayanja-Kizza; Joy Baseke; Htin Aung; David H Canaday; Koh Fujinaga
Journal:  AIDS Res Hum Retroviruses       Date:  2011-05-06       Impact factor: 2.205

2.  Cyclin T1 overexpression induces malignant transformation and tumor growth.

Authors:  Cristian Moiola; Paola De Luca; Kevin Gardner; Elba Vazquez; Adriana De Siervi
Journal:  Cell Cycle       Date:  2010-08-01       Impact factor: 4.534

3.  Targeting the ALK-CDK9-Tyr19 kinase cascade sensitizes ovarian and breast tumors to PARP inhibition via destabilization of the P-TEFb complex.

Authors:  Yu-Yi Chu; Mei-Kuang Chen; Yongkun Wei; Heng-Huan Lee; Weiya Xia; Ying-Nai Wang; Clinton Yam; Jennifer L Hsu; Hung-Ling Wang; Wei-Chao Chang; Hirohito Yamaguchi; Zhou Jiang; Chunxiao Liu; Ching-Fei Li; Lei Nie; Li-Chuan Chan; Yuan Gao; Shao-Chun Wang; Jinsong Liu; Shannon N Westin; Sanghoon Lee; Anil K Sood; Liuqing Yang; Gabriel N Hortobagyi; Dihua Yu; Mien-Chie Hung
Journal:  Nat Cancer       Date:  2022-10-17

Review 4.  Principles of interleukin (IL)-6-type cytokine signalling and its regulation.

Authors:  Peter C Heinrich; Iris Behrmann; Serge Haan; Heike M Hermanns; Gerhard Müller-Newen; Fred Schaper
Journal:  Biochem J       Date:  2003-08-15       Impact factor: 3.857

5.  Therapeutic targets for HIV-1 infection in the host proteome.

Authors:  Winnie S Liang; Anil Maddukuri; Tanya M Teslovich; Cynthia de la Fuente; Emmanuel Agbottah; Shabnam Dadgar; Kylene Kehn; Sampsa Hautaniemi; Anne Pumfery; Dietrich A Stephan; Fatah Kashanchi
Journal:  Retrovirology       Date:  2005-03-21       Impact factor: 4.602

6.  Ensemble-based modeling and rigidity decomposition of allosteric interaction networks and communication pathways in cyclin-dependent kinases: Differentiating kinase clients of the Hsp90-Cdc37 chaperone.

Authors:  Gabrielle Stetz; Amanda Tse; Gennady M Verkhivker
Journal:  PLoS One       Date:  2017-11-02       Impact factor: 3.240

7.  CDKI-73 is a Novel Pharmacological Inhibitor of Rab11 Cargo Delivery and Innate Immune Secretion.

Authors:  Alexandra Sorvina; Tetyana Shandala; Shudong Wang; David J Sharkey; Emma Parkinson-Lawrence; Stavros Selemidis; Douglas A Brooks
Journal:  Cells       Date:  2020-02-05       Impact factor: 6.600

8.  A specific selenium-chelating peptide isolated from the protein hydrolysate of Grifola frondosa.

Authors:  Yu Xiong; Zi-Hong Chen; Feng-Li Zhang; Zhi-Ying Yu; Bin Liu; Chong Zhang; Li-Na Zhao
Journal:  RSC Adv       Date:  2021-03-09       Impact factor: 3.361

9.  Deregulations in the cyclin-dependent kinase-9-related pathway in cancer: implications for drug discovery and development.

Authors:  Gaetano Romano
Journal:  ISRN Oncol       Date:  2013-06-06

Review 10.  Perspective of cyclin-dependent kinase 9 (CDK9) as a drug target.

Authors:  Vladimír Krystof; Sonja Baumli; Robert Fürst
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.